SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
Want to see SOPH full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.33Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call portrayed a broadly constructive operational and commercial story: strong top-line growth (22% YoY), record analysis volumes, healthy unit economics (high adjusted gross margin ~75%), improved net dollar retention (117%), and accelerating application and biopharma momentum. Management also took targeted cost actions, expanded liquidity and reaffirmed full-year guidance. Offsetting these positives were higher cash burn, an increased operating loss, FX translation headwinds (Swiss franc up ~14% vs USD), ongoing litigation costs, and softness in Latin America. Growth is expected to be back-half weighted, which introduces execution risk for the year. Overall, the company shows strengthening fundamentals and a clear path toward profitability, but faces near-term cost, FX and legal headwinds that require monitoring.Company Guidance
Strong Revenue Growth
Total revenue of $21.7M in Q1 2026, up 22% year-over-year from $17.8M in Q1 2025; company reaffirmed full-year 2026 revenue guidance of $92M–$94M (20%–22% growth).
Record and Growing Analysis Volume
Platform analysis volume reached ~108,000 in Q1 (up 16% YoY from 93,000) with a company record of >40,000 patients analyzed in March and 2.5M cumulative genomic profiles since inception.
High Adjusted Gross Margin and Profitability Progress
Adjusted gross margin of 75.4% in Q1 2026 (75.7% in Q1 2025) and adjusted gross profit of $16.4M, up 22% YoY; company expects modest gross margin expansion for 2026 and reaffirmed full-year adjusted EBITDA loss guidance of $29M–$32M (improved versus $41.5M in 2025).
Customer Base and Retention Strength
Core genomic customers increased to 537 (from 490 year-over-year); annualized revenue churn remained under 1%; net dollar retention improved to 117% (up from 103% YoY), indicating strong same-store expansion.
Regional and Application Momentum
U.S. volumes grew 28% YoY and APAC volumes grew 31%; EMEA revenue grew ~30% YoY (outperforming company average). Hem/Onc revenue grew 24% YoY and Rare/inherited volumes rose >20% as enhanced exome ramps.
Liquid Biopsy and New Application Adoption
3,000 liquid biopsy analyses in Q1 (up >100% YoY); 100 customers signed for MSK Impact/MSK Access in <2 years, with ~50% currently implementing PBM (expected revenue within 12 months).
Biopharma Momentum and Strategic Partnerships
Increasing biopharma traction with new contracts and partnerships including AstraZeneca, Johnson & Johnson, Kartos, and collaboration progress with Myriad; biopharma contributions turned modestly positive in Q1 and are expected to accelerate into 2027.
Capital and Liquidity Actions
Ended Q1 with $65.4M cash and equivalents (includes $14.5M ATM proceeds) and expanded credit facility by $25M with Perceptive Advisors, bolstering liquidity to support growth and litigation defense.
Operational Efficiency and AI-driven Cost Actions
Targeted cost actions in Q1 modestly reduced headcount and non-labor spend (focused on G&A and support/operations) and early internal rollout of productivity AI tools produced positive early results supporting operating leverage.
Technology and Long-term Strategic Positioning
Company reports scalable, hyper-efficient analytics platform with a unique global data footprint (data from 75 countries), prioritizing expansion into large NGS applications, MRD, multimodal capabilities and durable RWE/CDx offerings.
SOPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SOPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $5.29 | $5.07 | -4.16% |
Mar 03, 2026 | $4.62 | $4.10 | -11.26% |
Nov 04, 2025 | $5.00 | $4.68 | -6.40% |
Aug 05, 2025 | $3.30 | $3.42 | +3.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does SOPHiA GENETICS (SOPH) report earnings?
SOPHiA GENETICS (SOPH) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is SOPHiA GENETICS (SOPH) earnings time?
SOPHiA GENETICS (SOPH) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SOPH EPS forecast?
SOPH EPS forecast for the fiscal quarter 2026 (Q2) is -0.23.